Methotrexate Accord (Methotrexate)

Methotrexate blocks dihydrofolate reductase, halting the production of tetrahydrofolate needed for DNA and RNA synthesis. This limits the growth of rapidly dividing cells such as immune‑mediated inflammatory cells and cancer cells, and also increases extracellular adenosine, which contributes to its anti‑inflammatory properties.

The dose of Methotrexate Accord is individualized by the prescribing clinician based on the specific indication, disease severity, patient weight, renal and hepatic function, and response to therapy. No fixed regimen can be stated without a medical prescription.

Methotrexate is generally contraindicated in pregnancy because it can cause fetal malformations and embryotoxicity. It is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception during treatment and for a defined period after discontinuation.

To request Methotrexate Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Both methotrexate and leflunomide are conventional DMARDs used for rheumatoid arthritis, but methotrexate has a longer track record and is often considered first‑line because of its robust efficacy and extensive safety data. Leflunomide may be chosen when methotrexate is not tolerated, though it carries its own hepatic and teratogenic risks.

Methotrexate Accord should be stored refrigerated at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary temperature excursions occur, follow the supplier’s stability guidelines before use.

Methotrexate Accord is supplied as a sterile injectable solution for subcutaneous administration. It is typically injected into the abdomen, thigh or upper arm using a pre‑filled syringe or vial, following aseptic technique and the dosing schedule prescribed by the treating physician.

The most serious adverse events include bone‑marrow suppression leading to pancytopenia, severe liver injury or hepatitis, pulmonary fibrosis or interstitial pneumonitis, and acute renal failure. Early detection through regular laboratory monitoring and prompt reporting of symptoms such as persistent cough, jaundice, or unexplained bruising is essential.

Methotrexate Accord is contraindicated in patients with known hypersensitivity to methotrexate, severe hepatic impairment, uncontrolled renal dysfunction, active infections, and in pregnant or breastfeeding women unless the benefits outweigh the risks. Caution is also advised for individuals with pre‑existing blood dyscrasias or pulmonary disease.